Literature DB >> 21450826

Pivotal role of antibody and subsidiary contribution of CD8+ T cells to recovery from infection in a murine model of Japanese encephalitis.

Maximilian Larena1, Matthias Regner, Eva Lee, Mario Lobigs.   

Abstract

The immunological correlates for recovery from primary Japanese encephalitis virus (JEV) infection in humans and experimental animals remain poorly defined. To investigate the relative importance of the adaptive immune responses, we have established a mouse model for Japanese encephalitis in which a low-dose virus inoculum was administered into the footpads of adult C57BL/6 mice. In this model, ~60% of the mice developed a fatal encephalitis and a virus burden in the central nervous system (CNS). Using mice lacking B cells (μMT(-/-) mice) and immune B cell transfer to wild-type mice, we show a critically important role for humoral immunity in preventing virus spread to the CNS. T cell help played an essential part in the maintenance of an effective antibody response necessary to combat the infection, since mice lacking major histocompatibility complex class II showed truncated IgM and blunted IgG responses and uniformly high lethality. JEV infection resulted in extensive CD8(+) T cell activation, judged by upregulation of surface markers CD69 and CD25 and cytokine production after stimulation with a JEV NS4B protein-derived H-2D(b)-binding peptide and trafficking of virus-immune CD8(+) T cells into the CNS. However, no significant effect of CD8(+) T cells on the survival phenotype was found, which was corroborated in knockout mice lacking key effector molecules (Fas receptor, perforin, or granzymes) of cytolytic pathways triggered by T lymphocytes. Accordingly, CD8(+) T cells are mostly dispensable for recovery from infection with JEV. This finding highlights the conflicting role that CD8(+) T cells play in the pathogenesis of JEV and closely related encephalitic flaviviruses such as West Nile virus.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21450826      PMCID: PMC3094953          DOI: 10.1128/JVI.02611-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

Review 1.  SYFPEITHI: database for MHC ligands and peptide motifs.

Authors:  H Rammensee; J Bachmann; N P Emmerich; O A Bachor; S Stevanović
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

Review 2.  Japanese encephalitis.

Authors:  Scott B Halstead; Julie Jacobson
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

3.  Immunobiology of mosquito-borne encephalitic flaviviruses.

Authors:  Arno Müllbacher; Mario Lobigs; Eva Lee
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

4.  Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.

Authors:  Thomas P Monath; Farshad Guirakhoo; Richard Nichols; Sutee Yoksan; Robert Schrader; Chris Murphy; Paul Blum; Stephen Woodward; Karen McCarthy; Danell Mathis; Casey Johnson; Philip Bedford
Journal:  J Infect Dis       Date:  2003-10-03       Impact factor: 5.226

5.  Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus.

Authors:  Eva Lee; Mario Lobigs
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Protection of mice against experimental Japanese encephalitis virus infections by neutralizing anti-glycoprotein E monoclonal antibodies.

Authors:  A K Gupta; V J Lad; A A Koshy
Journal:  Acta Virol       Date:  2003       Impact factor: 1.162

7.  An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.

Authors:  Mario Lobigs; Megan Pavy; Roy A Hall; Päivi Lobigs; Peter Cooper; Tomoyoshi Komiya; Hiroko Toriniwa; Nikolai Petrovsky
Journal:  J Gen Virol       Date:  2010-02-03       Impact factor: 3.891

8.  B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus.

Authors:  Michael S Diamond; Bimmi Shrestha; Anantha Marri; Darby Mahan; Michael Engle
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  Clinical and immunological risk factors for severe disease in Japanese encephalitis.

Authors:  Daniel H Libraty; Ananda Nisalak; Timothy P Endy; Saroj Suntayakorn; David W Vaughn; Bruce L Innis
Journal:  Trans R Soc Trop Med Hyg       Date:  2002 Mar-Apr       Impact factor: 2.184

10.  CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis.

Authors:  Yang Wang; Mario Lobigs; Eva Lee; Arno Müllbacher
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more
  42 in total

Review 1.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

Review 2.  Encephalitis caused by flaviviruses.

Authors:  L Turtle; M J Griffiths; T Solomon
Journal:  QJM       Date:  2012-03

3.  Genetic and phenotypic properties of vero cell-adapted Japanese encephalitis virus SA14-14-2 vaccine strain variants and a recombinant clone, which demonstrates attenuation and immunogenicity in mice.

Authors:  Gregory D Gromowski; Cai-Yen Firestone; José Bustos-Arriaga; Stephen S Whitehead
Journal:  Am J Trop Med Hyg       Date:  2014-10-13       Impact factor: 2.345

4.  A Japanese encephalitis virus genotype 5 molecular clone is highly neuropathogenic in a mouse model: impact of the structural protein region on virulence.

Authors:  Mélissanne de Wispelaere; Marie-Pascale Frenkiel; Philippe Desprès
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

Review 5.  Viral diseases of the central nervous system.

Authors:  Phillip A Swanson; Dorian B McGavern
Journal:  Curr Opin Virol       Date:  2015-02-12       Impact factor: 7.090

6.  Development of a small animal peripheral challenge model of Japanese encephalitis virus using interferon deficient AG129 mice and the SA14-14-2 vaccine virus strain.

Authors:  Amanda E Calvert; Kandice L Dixon; Mark J Delorey; Carol D Blair; John T Roehrig
Journal:  Vaccine       Date:  2013-11-17       Impact factor: 3.641

7.  JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody.

Authors:  Maximilian Larena; Natalie A Prow; Roy A Hall; Nikolai Petrovsky; Mario Lobigs
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

8.  Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses.

Authors:  Kimberly A Dodd; Anita K McElroy; Megan E B Jones; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

9.  A Single Amino Acid Substitution in the M Protein Attenuates Japanese Encephalitis Virus in Mammalian Hosts.

Authors:  Mélissanne de Wispelaere; Cécile Khou; Marie-Pascale Frenkiel; Philippe Desprès; Nathalie Pardigon
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

10.  An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody.

Authors:  Nikolai Petrovsky; Maximilian Larena; Venkatraman Siddharthan; Natalie A Prow; Roy A Hall; Mario Lobigs; John Morrey
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.